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Abstract
Background: A better understanding of health-related quality of life (HRQoL) and psychological distress in cancer
survivors can raise awareness, promote the development of policies in cancer survivorship care, and facilitate better
targeted use of limited resources in low- and middle-income countries (LMICs). The main objectives of this paper
were therefore to assess HRQoL and the prevalence of psychological distress amongst cancer survivors in Southeast
Asia and identify risk factors of these outcomes.
Methods: The ACTION study was a longitudinal study in eight LMICs in Southeast Asia with 5249 first time cancer
survivors followed up at 1 year after diagnosis. HRQoL was assessed using the EORTC QLQ-C30 and EQ-5D.
Psychological distress (anxiety and depression) was assessed using the Hospital Anxiety and Depression Scale.
General linear models and multiple logistic regression were used to identify independent predictors of HRQoL and
psychological distress.
Results: One year after diagnosis, the mean EORTC QLQ-C30 global health score for survivors was 66.2 out of
100 (SD 22.0), the mean index score on the EQ-5D was 0.74 (SD 0.23), 37% of survivors had at least mild levels of
anxiety, and 46% showed at least mild levels of depression. Poorest HRQoL and highest prevalence of anxiety and
depression were seen in patients with lung cancer and lymphomas, while highest scores and least psychological
distress were seen in female patients with breast and cervical cancer. The most significant predictor of poor HRQoL
and psychological distress outcomes was cancer stage at diagnosis. Age, co-morbidities, treatment, and several
socioeconomic factors were associated with HRQoL and psychological distress.
Conclusions: Cancer survivors in LMICs in Southeast Asia have impaired HRQoL and substantial proportions have
psychological distress. Patients with advanced cancer stages at diagnosis and those in a poor socioeconomic
position were most at risk of such poor outcomes. Supportive interventions for cancer patients that address wider
aspects of patient wellbeing are needed, as well as policies that address financial and other barriers to timely
treatment.
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Background
Cancer is the world’s second leading cause of death and a
major cause of disability. In 2013, an estimated 8.2 million
individuals died of cancer, equating to 15% of all deaths
globally [1]. While cancer survival rates are improving in
high-income countries, cancer mortality rates are particu-
larly high in low- and middle-income countries (LMICs),
largely because of delays in diagnosis leading to presenta-
tion with advanced disease [2]. Breast cancer survival
rates, for instance, range from 80% or higher in North
America, Sweden and Japan to around 60% in middle-
income countries and below 40% in low-income countries
[3]. In addition, cancer affects populations in LMICs at
relatively young ages, resulting in long periods of ill-
health, great loss of productivity, and premature
deaths [2, 4]. The burden of cancer continues to in-
crease because of the ageing and growth of the popu-
lation alongside increasing levels of cancer-causing
behaviors such as smoking, physical inactivity, and
unhealthy dietary habits [2]. Thus, cancer threatens
health and economic development in LMICs and re-
quires urgent attention [5–8].
The ACTION study was a longitudinal study of 9513
newly diagnosed cancer patients in eight LMICs in
Southeast Asia, set up to prospectively assess the impact
of cancer on households’ economic wellbeing and health
[9]. Results of the study reported thus far have demon-
strated that families living in Southeast Asia struggled to
manage the costs associated with cancer care; over half
the households faced catastrophic out-of-pocket pay-
ments (defined as spending more than 30% of household
income for cancer-related costs) in the year after diagno-
sis [10, 11].
In addition to economic outcomes, key outcomes con-
sidered were health-related quality of life (HRQoL) and
psychological distress 1 year after diagnosis [9]. While
treatment has generally been completed a year after
diagnosis, the cancer burden may still be significant due
to short- and long-term sequelae that impair HRQoL
[12, 13]. Cancer survivors are at increased risk of cancer-
related fatigue and psychological symptoms [14–19]. Poor
health is an important barrier to get back to work or take
up activities of daily living after treatment [20, 21], thereby
putting individuals and families at risk of impoverishment.
However, few studies have been conducted in LMICs, and
awareness of health issues affecting cancer survivors is still
low [22, 23]. A better understanding of HRQoL and psy-
chological distress in cancer survivors can raise awareness,
promote the development of policies in cancer survivor-
ship care, and facilitate better targeted use of limited
resources [8].
The main objectives of this study were to assess
HRQoL and the prevalence of psychological distress
amongst cancer survivors in LMICs in Southeast Asia, 1
year after diagnosis. Secondary objectives were to iden-
tify demographic, clinical and socioeconomic predictors
of poor HRQoL and psychological distress.
Methods
Setting and participants
The ACTION study was a prospective longitudinal study
in which cancer patients from eight LMICs of ASEAN
(Cambodia, Indonesia, Laos, Malaysia, Myanmar,
Philippines, Thailand and Vietnam) were invited to par-
ticipate. Detailed methods have been published previ-
ously [9]. In brief, 9513 first-time cancer patients were
consecutively recruited from 47 sites, of which more
than 95% were public hospitals. Participants, aged 18
years and over, were interviewed by study staff at base-
line (within 12 weeks after clinical diagnosis) and at 3
and 12 months after diagnosis. One year after diagnosis,
29% (n = 1993) of the initial study population had died
and 24% (n = 2271) were lost to follow-up. The
remaining 5249 survivors were contactable at 12 months
and were included in this report.
The ACTION study was approved by the University of
Sydney Human Research Ethics Committee. Approvals
from local institutional ethics committees and other
regional or national regulatory bodies were obtained
prior to the initiation of the study in any site (Additional
file 1). Written informed consent, complying with local,
regional, and national requirements, was obtained from
all participants prior to entry into the study.
Patient-reported health outcomes
Cancer-specific HRQoL was assessed by the European
Organisation for Research and Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ) C30
(version 3.0). Official translations were available for all
countries except Laos and Cambodia [24]. The following
were assessed: global health status, role function, cognitive
function, physical function, emotional function, social
function, fatigue, nausea and vomiting, pain, dyspnea,
insomnia, appetite, constipation, and diarrhea. Scores are
presented on a linear scale of 0 to 100. Higher scores
correspond to better HRQoL in the function and global
health scales, whereas higher scores in symptom scales
and items represent more problems with symptoms [25].
Generic HRQoL was assessed using the EuroQol-5
dimensions questionnaire (EQ-5D) [26], which com-
prises five items relating to problems in mobility, self-
care, usual activities, pain and discomfort, and anxiety
and depression. The EQ-5D index provides a valuation
of HRQoL in which full health is scored at 1, and death
is 0 [27]. Official translations were provided by the
EuroQoL group for all countries except Laos and
Cambodia, covering 96% of the study population.
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Psychological distress was measured using the Hospital
Anxiety and Depression Scale (HADS), which measures
generalized anxiety and depression experienced during
the past week with two subscales: anxiety (HADS-A)
and depression (HADS-D) [28]. The HADS is a self-
report instrument and has been widely used in cancer
patients [29]. A cut-off of ≥ 8 on the HADS-D scale
and ≥ 9 on the HADS-A was used to indicate cases of
least mild depression and anxiety, respectively [29]. Offi-
cial translations were available for Indonesia, Malaysia,
Philippines and Thailand, covering 63% of the study
population.
In cases where a formal translation was not available,
questionnaires were translated using forward-translation
and back-translation following WHO guidelines for the
process of translation of questionnaires [30].
Predictor variables
We considered a range of demographic, socioeconomic
and clinical variables as putative predictors of HRQoL
and psychological distress. The demographic and socio-
economic variables considered were collected through
self-reported questionnaires and relate to the time of
entry to the study (baseline). Demographic variables
considered were age, sex, marital status, and country of
residence. Socioeconomic variables considered were
household income (grouped into low (0–75% of mean
national income), middle (75–125%) and high income
(>125%)), economic hardship (whether in the 12 months
previous to baseline they were unable to make necessary
household payments or needed assistance to do so [31]),
employment status (paid work), health insurance status,
and highest level of education attained. Clinical variables
obtained from medical records at baseline comprised
cancer site, cancer stage at diagnosis (clinical TNM
classification), and pre-existing chronic conditions.
Treatment modality was ascertained at the end of study
(12 months after baseline).
Statistical analyses
Descriptive statistics were used to report the distribution
of demographic, socioeconomic and clinical characteris-
tics of the full study population, and separately by sex.
The distribution of HRQoL scores and prevalence of
anxiety and depression at 12 months was determined for
the study population, the most common cancer types
(those with more than 200 cases), and other potential
predictors of these outcomes. Evidence-based guidelines
for the interpretation of differences in EQ-5D and QLQ-
C30 scores were used [32, 33]. For example, an observed
mean difference of < 4 points on the QLQ-C30 global
health scale was considered trivial and unlikely to have
clinical relevance [34]. General linear models for HRQoL
endpoints and multiple logistic regression for anxiety
and depression were used to determine the association
between predictor variables and study outcomes. To
limit the number of tests and its associated increased
likelihood of a type I error occurring, multivariable ana-
lyses were conducted for selected outcomes; global health,
physical function, emotional function, fatigue, and pain.
These outcomes are hypothesized to be most distinctive
for the long-term health of different subgroups of cancer
patients [21]. Stratified analyses explored the impact of
predictor variables across the most common cancer types.
Results
Study sample
Characteristics of the 5249 survivors followed-up at 12
months are shown in Table 1; Additional file 2: Table S1A
details the characteristics by sex. The mean age of the
study population was 52 years (range, 18–100) and 69%
were female. Almost half of the participants (n = 2365,
45%) were from lower middle-income countries
(Laos, Indonesia, Vietnam, and the Philippines),
followed by upper middle-income countries (Malaysia
and Thailand; n = 2199, 42%) and low-income countries
(Cambodia and Myanmar; n = 685, 13%).
The most common cancer types were breast (32%),
cervix (11%), mouth and pharynx (11%), colon and
rectum (11%), and lymphomas (5%). Among patients
with available data on cancer stage (n = 3172), 14% pre-
sented with stage I, 38% with stage II, 31% with stage III,
and 17% with stage IV cancers, whereas hematological
cancers were diagnosed in 436 patients (8%). Fifty-six
percent of participants had surgery as part of treatment,
68% had chemotherapy and 46% had radiotherapy (not
mutually exclusive).
In females, cancer of the breast (45%) and cervix
(17%) were most common. Among males, mouth (23%)
and colorectal (19%) cancer were most common. Of
female participants, 35% presented with stage I or II
cancer compared to only 18% of males.
Patient-reported health outcomes
A year after diagnosis, the mean global health score for
survivors was 66.2 (SD 22.0) on the QLQ-C30 (Table 2).
Scores on function scales ranged from 73.7 (SD 26.6) for
social functioning, to 79.0 (SD 22.8) for physical func-
tion and 86.2 (SD 20.7) for cognitive functioning. In
terms of symptoms, highest scores (i.e., more symptoms)
were reported for fatigue (24.7), pain (21.4), and insom-
nia (21.2). The mean index score on the EQ-5D was 0.74
(SD 0.23). In terms of psychological distress, a year after
diagnosis, anxiety was seen in 37% of survivors and
depression in 46%.
Poorer outcomes, i.e., lowest HRQoL scores and
highest symptom scores, were consistently seen in lung
cancer and lymphoma patients (Fig. 1a–c, Additional file 2:
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Table S2A). Mean QLQ-C30 global health scores were
respectively 56.5 (SD 23.2) and 52.8 (SD 27.2) for lung and
lymphoma, compared to 74.2 (SD 17.7) and 69.7 (SD 19.4)
for cancers of the cervix and breast. Similarly, the propor-
tion of patients reporting moderate or severe problems on
the EQ-5D domains was highest for lung cancer and
lymphomas (Fig. 1d). The EQ-5D index scores for lung
Table 1 Demographic, socioeconomic, and clinical




< 45 1569 30
45–54 1577 30
55–64 1369 26









0–6 years (primary) 1932 37
7–12 years (secondary) 2169 41


















Missing 1 < 1
Experienced economic hardship in the year before diagnosis
Yes 2643 50
No 2605 50
Missing 1 < 1
Paid work (patient level) before diagnosis (self-employed or for a wage)
Yes 2481 47
No 2768 53
Table 1 Demographic, socioeconomic, and clinical
characteristics of the study population (n = 5249) (Continued)
Cancer site
Mouth and pharynx 571 11
Esophagus 49 < 1
Stomach 143 3
Colon and rectum 552 11
Liver 26 < 1
Pancreas 26 < 1
Trachea, bronchus and lung 226 4





Prostate 27 < 1
Bladder 20 < 1
Lymphomas and multiple myeloma 241 5
Leukemia 195 4
Other malignant neoplasms 617 12
Missing 36 < 1
Cancer (TNM) stage at diagnosis
Stage I 437 8
Stage II 1190 23
Stage III 984 19
Stage IV 561 11






Hormonal therapy 496 9
Pre-existing chronic conditions (as reported in medical files)
0 4032 77
1 839 16
≥ 2 352 7
Missing 26 < 1
aCategories are not mutually exclusive since most patients received a
combination of treatments
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cancer and lymphomas were 0.63 (SD 0.24) and 0.69 (SD
0.24), respectively, compared to 0.76 (SD 0.21) and 0.78
(SD 0.21) for cancers of the breast and cervix, respectively.
The proportion of patients with psychological distress was
also highest among lung and lymphoma cancer patients;
60% of these patients report depression and anxiety was
seen in 50% of lung cancer patients and 58% of lymphoma
patients. Highest HRQoL scores, lowest symptom burden
and lowest prevalence of anxiety and depression were seen
in patients with cancer of the cervix.
HRQoL outcomes and psychological distress for sub-
groups of patients are presented in Table 3. Clinically
meaningful differences in HRQoL scores (i.e., > 4 points
difference on EORTC scales) were seen between partici-
pants older than 65 years compared to those younger
than 45 years (e.g., EQ-5D index of 0.67 (SD 0.25) vs.
0.76 (SD 0.22), physical function of 72.6 (SD 28.0) vs.
81.9 (SD 21.5)). Older participants also reported more
anxiety (45% vs. 36%) and depression (56% vs. 43%) than
participants younger than 45 years. Male cancer survi-
vors reported lower HRQoL scores on the EQ-5D, the
QLQ-C30 function scales, and for fatigue and pain, but
mean differences are considered trivial [34]. The preva-
lence of anxiety (42% vs. 35%) and depression (52% vs.
43%), however, is substantially higher in males than in
females. The socioeconomic variables household income
(low vs high), economic hardship, and not being in paid
work were all associated with lower HRQoL scores, but
differences were small. Nevertheless, a high income and
paid work were associated with fewer cases of anxiety
and depression. Health insurance was not associated
with HRQoL and psychological distress.
Cancer stage at diagnosis and co-morbidities were
associated with HRQoL and psychological distress. Di-
rections were as expected; a more advanced cancer stage
and more than two pre-existing chronic conditions were
associated with lower HRQoL scores (all endpoints) and
more cases of psychological distress.
Findings from the multivariable linear model showed
that, in general, predictor variables, except treatment
modalities (radiotherapy and chemotherapy), had a
significant independent impact on HRQoL and psycho-
logical distress (Table 4). HRQol scores decreased, and
the odds of psychological distress increased, with in-
creasing age. Males had lower emotional function scores
and higher odds of psychological distress compared to
females. Other HRQoL outcomes were not affected by
sex. Being married (vs. unmarried) positively impacted
on physical and emotional function (QLQ-C30), but not
on global health, the EQ-5D index, and psychological
distress. Cancer stage at diagnosis was the strongest pre-
dictor with clinically meaningful reductions in HRQoL
and psychological distress; stage IV and hematological
cancers were predictive of severely impaired HRQoL (all
endpoints) and the odds of having anxiety or depression.
Having multiple chronic conditions was an important
predictor for poor HRQoL and psychological distress. A
high income (vs. low) and being in paid work positively
impacted on most HRQoL outcomes and were associ-
ated with lower odds of psychological distress. Health
insurance was associated with higher global health
scores, but lower scores for physical function, pain and
fatigue, and slightly higher odds of depression.
Multivariable models stratified by cancer type showed
that stage at diagnosis was the most important predictor
of HRQoL and psychological distress across breast,
cervical, lung, mouth, colorectal cancer, and lymphomas
(Additional file 2: Tables S4A–F). In addition, a range of
socioeconomic variables were associated with HRQoL
endpoints and psychological distress across these cancer
types. Results of the stratified analyses must be inter-
preted with caution because the models (except for
breast cancer) were generally underpowered and could
therefore only detect the strongest predictors.
Discussion
One year after diagnosis, we identified impaired HRQoL
and a prevalence of anxiety of 37% and depression of
Table 2 Health-related quality of life (HRQoL) and psychological
distress 1 year after diagnosis
All cancers (n = 5249)
HRQoL
Cancer-specific HRQoL (EORTC QLQ-C30) Mean SD
Global health 66.2 22.0
Physical function 79.0 22.8
Emotional function 76.2 24.8
Role function 74.8 28.8
Cognitive function 86.2 20.7










Index score 0.74 0.23
Psychological distress N %
HADS-A: Anxiety 1933 37
HADS-D: Depression 2394 46
HADS Hospital Anxiety and Depression Scale
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46% amongst cancer survivors in LMICs in Southeast
Asia. Differences in HRQoL and psychological distress
were observed based on age, sex, household income,
cancer type, and stage at diagnosis. In general, older pa-
tients, males, patients with lung cancer or lymphomas,
an advanced stage at diagnosis, low income status, and
those not in paid work reported lowest HRQoL scores
and were most likely to report anxiety and depression.
Female patients with cancer of the breast and cervix
showed the most favorable outcomes reflecting a better
prognosis for these type of cancers [2]. An advanced
cancer stage at diagnosis was the strongest independent
predictor of poor HRQoL outcomes and psychological
distress. In addition, increasing age, having multiple
chronic conditions, and several socioeconomic variables
were identified as being independently associated with
poor outcomes.
Inevitably, comparison of HRQoL and psychological
distress with earlier studies is rough due to the varying
settings, cancer types, and measures used. We are aware
of few studies among cancer survivors in Southeast Asia
or other LMICs [19, 35]. Most research on cancer sur-
vivorship has been conducted in high-income settings
where patients were more likely to receive a timely diag-
nosis, optimal treatment, follow-up, and survivorship
care. Survival rates, therefore, differ drastically between
countries but, regardless of setting, many cancer survi-
vors experience symptom burden, loss of HRQoL, and
(at least mild) psychological distress in the first year after
treatment [12, 13, 36, 37]. Cancer stage is widely recog-
nized as an important clinical determinant of HRQoL in
cancer survivors [12, 19, 37–42]. A diagnosis of lung
cancer and having comorbid conditions are also asso-
ciated with a high symptom burden and low HRQoL
[12, 13, 36, 37]. In both low- and high-income settings,
socioeconomic disparity in cancer survivors has been
associated with poor HRQoL [12, 13, 35, 42–45] and
psychological distress [46, 47]. Possible explanations may
be poorer recognition of cancer symptoms and more bar-
riers to access appropriate and timely healthcare services
by patients with low socioeconomic status [48]. Patients
with a poor socioeconomic position are also less likely to
receive appropriate follow-up care and discuss concerns
with their healthcare providers [49]. Our study has gener-
ally confirmed the relationship between poor socioeco-
nomic position (e.g., a low household income, not being in
Fig. 1 Health-related quality of life and psychological distress among cancer survivors (n = 5249) 1 year after diagnosis. a EORTC QLQ-C30 function
scales, b EORTC QLQ-C30 symptom scales, c HADS anxiety and depression: proportion of survivors with anxiety and depression), and d EQ-5D
domains: proportion of survivors with moderate or severe problems
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Table 3 Demographic, socioeconomic, and clinical characteristics of the study population (n = 5249) and their associations with
health-related quality of life (HRQoL) and psychological distress at 1 year after diagnosis as measured by the EORTC QLQ-C30, EQ-5D,
and HADS
HRQoL Psychological distress
Generic HRQoL Cancer-specific HRQoL (EORTC QLQ-C30)
EQ-5D indexa Physical function Emotional function Global health Pain Fatigue Anxiety Depression
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) N (%) N (%)
Age group, years
< 45 0.76 (0.22) 81.9 (21.5) 77.8 (24.0) 67.0 (23.0) 19.2 (24.1) 21.6 (24.0) 570 (36) 678 (43)
45–54 0.75 (0.22) 80.9 (21.9) 76.7 (24.2) 67.5 (21.1) 20.7 (25.7) 23.5 (24.6) 513 (33) 663 (42)
55–64 0.73 (0.23) 77.9 (22.1) 75.8 (24.4) 65.9 (21.0) 22.1 (24.9) 26.1 (24.9) 519 (38) 644 (47)
≥ 65 0.67 (0.25) 70.5 (26.1) 72.6 (28.0) 62.6 (23.3) 31.4 (28.3) 31.4 (28.3) 330 (45) 408 (56)
Sex
Female 0.75 (0.22) 80.1 (21.7) 76.8 (24.4) 66.2 (18.1) 20.2 (24.5) 23.9 (24.8) 1262 (35) 1560 (43)
Male 0.71 (0.24) 76.5 (24.8) 75.0 (25.5) 62.3 (20.0) 24.1 (27.0) 26.6 (26.0) 671 (42) 834 (52)
Marital status
Married 0.74 (0.23) 79.2 (22.5) 76.5 (24.3) 66.7 (21.6) 21.5 (25.3) 24.6 (25.0) 1501 (37) 1845 (46)
Not married 0.73 (0.23) 78.3 (23.6) 75.5 (26.3) 64.9 (23.5) 21.1 (25.7) 24.9 (26.1) 432 (36) 549 (46)
Level of education
0–6 years (primary) 0.73 (0.23) 77.8 (24.1) 77.1 (24.8) 68.1 (21.6) 21.5 (26.1) 24.2 (25.7) 641 (33) 849 (44)
7–12 years (secondary) 0.74 (0.23) 79.1 (21.8) 75.4 (24.2) 64.3 (21.4) 22.1 (24.8) 25.7 (24.7) 908 (42) 1088 (50)
> 12 years (tertiary) 0.75 (0.22) 80.8 (22.2) 76.3 (25.8) 66.8 (23.5) 19.9 (25.2) 23.7 (25.4) 384 (33) 457 (40)
Household income
Low (0–75%) 0.71 (0.23) 76.5 (24.9) 74.0 (25.8) 64.9 (23.2) 23.3 (27.0) 25.4 (26.4) 712 (43) 818 (50)
Med (75–125%) 0.72 (0.23) 78.3 (21.8) 76.0 (24.3) 65.1 (22.1) 21.5 (24.9) 23.6 (24.2) 420 (40) 526 (50)
High (> 125%) 0.78 (0.22) 81.6 (21.2) 78.0 (24.4) 67.1 (20.7) 18.7 (23.8) 24.0 (24.5) 510 (28) 685 (38)
Health insurance
Yes 0.75 (0.22) 78.6 (24.2) 76.9 (24.8) 68.0 (21.4) 22.7 (26.3) 25.9 (26.1) 813 (36) 1022 (46)
No 0.73 (0.23) 79.3 (21.6) 75.7 (24.8) 64.9 (22.4) 20.4 (24.6) 23.8 (24.5) 1120 (38) 1372 (46)
Economic hardship
Yes 0.73 (0.23) 77.1 (24.9) 75.2 (25.9) 67.8 (22.0) 23.6 (27.5) 26.6 (27.1) 949 (36) 1217 (46)
No 0.75 (0.22) 80.9 (20.2) 77.3 (23.6) 64.7 (22.0) 19.2 (22.8) 22.8 (23.0) 984 (38) 1177 (45)
Paid work
Yes 0.75 (0.22) 80.9 (22.2) 77.0 (24.9) 67.3 (21.8) 19.5 (25.1) 22.7 (24.8) 787 (32) 996 (40)
No 0.72 (0.23) 77.2 (23.2) 75.5 (24.7) 65.3 (22.2) 23.1 (25.6) 26.5 (25.5) 1146 (42) 1398 (51)
Cancer stage at diagnosis
Stage I 0.81 (0.20) 85.7 (15.8) 82.3 (18.9) 74.2 (18.3) 12.5 (18.0) 16.6 (19.5) 99 (23) 141 (32)
Stage II 0.79 (0.21) 83.6 (18.6) 79.9 (22.8) 71.5 (18.9) 15.7 (21.1) 20.0 (22.0) 323 (27) 424 (36)
Stage III 0.75 (0.22) 79.6 (23.3) 76.0 (25.3) 69.0 (21.6) 20.4 (26.1) 24.0 (25.6) 296 (30) 400 (41)
Stage IV 0.65 (0.24) 69.8 (29.0) 63.4 (34.7) 57.0 (23.8) 32.6 (32.0) 36.6 (32.3) 265 (47) 327 (58)
None (hematological
cancers)
0.67 (0.23) 77.4 (18.6) 77.9 (18.6) 44.7 (26.8) 21.1 (21.0) 22.1 (19.6) 308 (71) 313 (72)
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paid work, and having experienced economic hardship)
and impaired HRQoL and psychological distress, with one
exception; primary education only was consistently associ-
ated with better study outcomes. While the absence of an
association between education and HRQoL has been re-
ported in certain cancer types and countries [36, 50], few
studies find this inverse relationship between education
and HRQoL [51]. To rule this out as a chance finding, this
observation warrants further investigation. Another not-
able finding was that patients with health insurance were
not necessarily better off than those without. These
results, however, need to be interpreted with caution as
we did not have data on benefit packages provided by the
various health insurance schemes and associated processes
of care. For example, Malaysia has achieved universal
coverage that includes cancer care, but healthcare is
provided through public health facilities that may have
long waiting times [52].
Our study has a number of limitations. First, participa-
tion in the study was voluntary and, as such, the propor-
tion of cases observed for individual cancers were not
representations of population incidences. Clinicians
responsible for enrolling patients into the study appear to
have under-recruited those with the most virulent types of
cancer such as lung and liver cancers. Second, by one year,
23% of the original study population had died and 24%
were lost to follow-up. The high loss to follow-up is unfor-
tunate, but not surprising, and may have introduced re-
sponse bias. It is plausible that patients with poor HRQoL
after treatment may have been less interested or too ill to
continue participation; patients who completed the 12
months follow-up were more likely to have stage I or II
cancer (Additional file 2: Table S1B). These first two limita-
tions may have resulted in an underestimate of HRQoL
and the prevalence of psychological distress in this patient
population. Third, while HRQoL and psychological distress
were measured upon study entry (within 12 weeks after
clinical diagnosis), and at 3 and 12 months, we did not
report change scores since the first two measurements are
likely to reflect the type and timing of treatment (e.g.,
recovery from surgery, having second line treatment or just
supportive care) as opposed to underlying HRQoL, and
thus changes in scores may be transient fluctuations
caused by treatment course. Fourth, while widely endorsed
as one of the best available measures of anxiety and depres-
sion, the use of the HADS across languages and cultures
has recently been criticized, e.g., there may be an unknown
influence of linguistic and cultural factors on cut-points for
anxiety and depression [53]. As such, there may be con-
cerns that items in the translated version may differ con-
ceptually to the original version. In our study, this risk may
been pronounced in approximately 36% of the sample
where official translations of the original questionnaires
were not available and we had to undertake our own. Re-
sults presented here regarding prevalence must therefore
be interpreted with caution. Nevertheless, the HADS was
used for the purpose of subgroup comparisons and
correlations rather than a screening tool, and therefore
results provide useful insight into groups of patients with
higher prevalence of anxiety and depression as well as risk
factors. Finally, it was not possible to compare mean
HRQoL scores of the cancer population to scores of the
general population due to the lack of reference scores for
Southeast Asia.
Despite limitations, our study is unique in being obser-
vational, including a large population of cancer survivors
in an LMIC setting, and using a range of well-validated
measures that characterize wellbeing in cancer patients.
Until now, high-quality data on the quality of life lived
with cancer have been lacking in ASEAN populations.
Table 3 Demographic, socioeconomic, and clinical characteristics of the study population (n = 5249) and their associations with
health-related quality of life (HRQoL) and psychological distress at 1 year after diagnosis as measured by the EORTC QLQ-C30, EQ-5D,
and HADS (Continued)
Treatmentb
Surgery 0.78 (0.22) 82.1 (21.2) 78.7 (25.2) 69.9 (20.5) 17.9 (24.5) 22.1 (25.3) 1051 (36) 1051 (36)
No surgery 0.68 (0.23) 74.8 (24.1) 72.9 (24.1) 61.4 (23.2) 25.7 (25.8) 27.9 (24.9) 1123 (51) 1322 (60)
Radiotherapy 0.73 (0.22) 78.6 (22.5) 76.1 (24.4) 67.0 (21.7) 20.1 (24.9) 25.3 (25.0) 881 (36) 1123 (46)
No radiotherapy 0.74 (0.23) 79.2 (22.9) 76.2 (25.3) 65.5 (22.5) 22.5 (25.8) 24.0 (25.5) 1026 (38) 1248 (46)
Chemotherapy 0.73 (0.23) 78.6 (22.7) 75.2 (25.2) 65.0 (22.9) 21.7 (25.6) 25.3 (25.6) 1330 (38) 1652 (47)
No chemotherapy 0.76 (0.23) 79.7 (23.0) 78.4 (23.9) 69.0 (20.2) 20.2 (24.7) 23.1 (24.6) 580 (36) 732 (45)
Pre-existing chronic conditions
0 0.74 (0.23) 79.6 (22.4) 76.8 (24.0) 66.3 (22.0) 21.1 (25.1) 24.0 (24.8) 1503 (37) 1853 (46)
1 0.74 (0.23) 79.0 (22.8) 77.2 (24.7) 66.5 (21.7) 20.4 (24.8) 24.2 (24.9) 266 (32) 357 (43)
≥ 2 0.67 (0.23) 71.5 (25.1) 67.5 (31.7) 64.8 (23.7) 27.5 (29.5) 34.6 (29.3) 159 (45) 177 (50)
aIndex scores based on Thai tariff
bCategories are not mutually exclusive since most patients received a combination of treatments
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Results from this study should encourage governments
in the region to take action to develop national cancer
control strategies and extend national health insurance
initiatives to remove barriers to early diagnosis and
prompt treatment [2, 8]. Awareness education and
screening for detectable cancers may result in a larger
proportion of patients presenting with early stage can-
cers that are more likely to be able to receive curative
and less invasive treatment options, leading to cost
savings and a reduction in mortality [54, 55], as well as
to better HRQoL and lower levels of psychological dis-
tress among survivors, as found herein. Following (early)
diagnosis, governments should ensure access to appro-
priate and quality treatment, including medication for
cancer [6]. The focus of this paper, however, is on the
needs of cancer survivors. Supportive and survivorship
care, i.e., the prevention and management of the adverse
effects of cancer and its treatment are increasingly
recognized as critical components of quality cancer care
and cancer control programs. Yet, in resource-constrained
health systems, survivorship care is often overlooked
[56–58]. Consensus statements and recommendations
have been developed, mainly for breast cancer, to
illustrate how health systems in LMICs can provide
appropriate cancer care, including survivorship care,
taking resource constraints into account [22, 56, 59].
Most recommendations can be generalized to other
cancers. First, at the health system level, appropriate
follow-up care (in terms of frequency and intensity)
after completion of initial treatment is needed to
monitor for possible recurrences or new cancers and
adverse effects of treatments [22]. Scheduled follow-
up visits, and the name of the health professional
responsible for post-treatment care, should be docu-
mented in a patient’s individual care and survivorship
plan [60]. This document should also include details
of the patient’s treatment protocol so that potential
specific treatment-related complications and long-
term physical side effects can be considered [56, 59].
Importantly, assessment of psychosocial needs, includ-
ing depression, anxiety, emotional distress, and
changes to social roles, should be part of the follow-up
care provided. Health professionals need (additional)
education about the recognition and management of
long-term physical complications and psychosocial com-
plications of survivorship [22]. In addition, patients must
be educated on symptoms of disease recurrence and life-
style modifications to reduce cancer risk and improve
quality of life [22, 59]. Our findings emphasize that pa-
tients in poor socioeconomic positions (e.g., low income,
unemployed) and patients with late-stage cancers are at
highest risk for poor HRQoL and psychological distress
and therefore policies are needed to address the financial
burden of treatment, including the expansion of national
insurance programs and other social safety nets to offset
the indirect costs incurred by patients and their families.
Survivorship interventions should address wide aspects of
wellbeing and are ideally implemented as part of routinely
offered programs of care. Governments and research orga-
nizations should encourage this type of cancer (survivor-
ship) research and accelerate the translation of research
findings into clinical and public health practice [6].
Conclusions
This study provides valuable insight into the cancer burden
in terms of HRQoL and psychological distress and risk
factors for poor outcomes in low- and middle-income
settings. Improving cancer awareness, early detection,
prompt treatment, and appropriate survivorship care are
the major public health and clinical approaches to improve
the health and wellbeing of cancer survivors. Importantly,
this study demonstrates that supportive interventions for
cancer patients that address wider aspects of patient
wellbeing are needed, including government initiatives to
address the economic burden associated with treatment.
Results can be used to support policies geared towards sur-
vivorship care and inform research evaluating supportive
interventions.
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